Effects of Remimazolam on Postoperative Myocardial Injury

Enrolling by invitation · Not applicable

Conditions studied: Myocardial Injury

In brief

This study is designed as a prospective, double-blind, randomized controlled trial to investigate the effect of remimazolam on intraoperative cardiac output (CO) in elderly patients undergoing general anesthesia, and to evaluate its protective efficacy against elevated high-sensitivity cardiac troponin T (hs-cTnT) levels and perioperative myocardial injury.

Key facts

Study ID

NCT07725185

Run by

Affiliated Hospital of Jiaxing University

People needed

80

Starts

2026-08-01

Expected to finish

2029-06-01

Last updated by the study team

2026-07-24

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 65 years
• Elderly hospitalized patients scheduled to undergo general anesthesia
• American Society of Anesthesiologists (ASA) physical status I-III
• Surgery to be performed in the supine position
• Ability to communicate with the investigator and to cooperate in completing the assessment scales
• Expected duration of surgery ≥ 2 hours

You may not qualify if…

• Congenital heart disease, severe cardiac conduction block, or implanted cardiac pacemaker;
• History of cerebral infarction, cerebral hemorrhage, or stroke within the past 3 months;
• Known allergy to remimazolam or propofol;
• Severe mental illness, history of analgesic abuse, or addiction to psychotropic drugs;
• Patient or family members refuse surgery or anesthesia, or are unable to complete the required questionnaires.

Where it is running

• Jiaxing University Affiliated Hospital — Jiaxing, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.